PIQHASSO

orange__line

Official Title: An open-label, non-randomized, multicentre phase 1/ 2b study investigating safety and efficacy of PQR309 and eribulincombination in patients with locally advanced or metastatic HER2 negative and triple-negative breast cancer.

This study is an open-label,non randomized, multi-center, phase 1/2b (dose escalation followed by expansion part) study evaluating clinical safety, efficacy and pharmacokinetics of PQR309 in combination with standard dose of eribulin in patients with locally advanced or metastatic HER2-negative (escalation part) and Triple Negative Breast Cancer (expansion part).

Legal Study Sponsor is PIQUR Therapeutics AG


PIQHASSO at clinicaltrials.gov
TUMOR TYPE PHASE N SITES COUNTRY STATUS
Breast I/IIb Phase I: 38
Phase IIb: 14-28
Phase I: 6
Phase IIb: 10
Spain, UK Recruitment Closed

SABCS 2016 – Download the abstract